Identification of Novel Fibrosis Modifiers by In Vivo siRNA Silencing
Name
1-s2.0-S2162253117301646-main.pdf
Description
Published version
Size
1.24 MB
Format
Adobe PDF
Checksum (MD5)
5b1294da37f7d2fc313975bf0cd2260d
Author(s)
Kauffman, Kevin John
Mir, Faryal
Anderson, Daniel Griffith
Date Issued
June 2017
Journal
Molecular Therapy: Nucleic Acid
Publisher
Elsevier BV
Citation
Vollmann, Elizabeth H., Lizhi Cao, Aldo Amatucci, Taylor Reynolds, Stefan Hamann, Isin Dalkilic-Liddle, Thomas O. Cameron, Markus Hossbach, Kevin J. Kauffman, Faryal F. Mir, Daniel G. Anderson, Tatiana Novobrantseva, Victor Koteliansky, Tatiana Kisseleva, David Brenner, Jeremy Duffield, and Linda C. Burkly. "Identification of Novel Fibrosis Modifiersby In Vivo siRNA Silencing." Molecular Therapy: Nucleic Acids 7, June 2017 © 2017 The Author(s)
Version
Final published version
Abstract
Fibrotic diseases contribute to 45% of deaths in the industrialized world, and therefore a better understanding of the pathophysiological mechanisms underlying tissue fibrosis is sorely needed. We aimed to identify novel modifiers of tissue fibrosis expressed by myofibroblasts and their progenitors in their disease microenvironment through RNA silencing in vivo. We leveraged novel biology, targeting genes upregulated during liver and kidney fibrosis in this cell lineage, and employed small interfering RNA (siRNA)-formulated lipid nanoparticles technology to silence these genes in carbon-tetrachloride-induced liver fibrosis in mice. We identified five genes, Egr2, Atp1a2, Fkbp10, Fstl1, and Has2, which modified fibrogenesis based on their silencing, resulting in reduced Col1a1 mRNA levels and collagen accumulation in the liver. These genes fell into different groups based on the effects of their silencing on a transcriptional mini-array and histological outcomes. Silencing of Egr2 had the broadest effects in vivo and also reduced fibrogenic gene expression in a human fibroblast cell line. Prior to our study, Egr2, Atp1a2, and Fkbp10 had not been functionally validated in fibrosis in vivo. Thus, our results provide a major advance over the existing knowledge of fibrogenic pathways. Our study is the first example of a targeted siRNA assay to identify novel fibrosis modifiers in vivo.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/J.OMTN.2017.04.014
